OBJECTIVE:
Most patients with differentiated thyroid cancer (DTC) have an excellent prognosis after receiving standard treatment, consisting of surgery and often adjuvant radioactive iodine (RAI). However, a subgroup of patients prove to have progressive DTC which is refractory to RAI (RRDTC). Treatment options for RRDTC are limited. This study investigated the treatment patterns and health care resource utilization of patients with RRDTC.
METHODS:
Data were collected by performing a retrospective chart review study in the US and 5EU (France, Germany, Italy, Spain, UK) with physicians recruited from an online panel. Physicians provided clinical information on 1 to 4 of their RRDTC patients in an online survey. Demographics, disease history, treatment information, and healthcare resource were included and reported descriptively. Healthcare resource use was compared across treatment classes using general linear models. RESULTS*: 211 physicians participated and provided a total of 623 patient charts (43.0% of charts were from the US and 11-12% from each 5EU country). 44.0% of patients were male with a mean age at diagnosis of 58.2 years (SD=12.4). 50.8% of patients were treated with systemic treatment (e.g., 31.8% multi-kinase inhibitors [MKIs] ; 16.4% cytotoxic chemotherapy). The remaining 49.2% were either in a watch and wait ("WW") or had received local therapy only (e.g., having received external beam radiation or TSH therapy). Overall, patients averaged 15.26 days hospitalized collectively (due to disease-related complications or side effects). There were no significant differences between those managed by systemic therapy (e.g., MKIs, cytotoxic chemotherapy, or selective BRAF-inhibitors) and those managed by WW or local therapy only.
CONCLUSIONS:
Among patients diagnosed with RRDTC, WW and non-systemic management options remain common. A large direct-cost burden may be observed given the frequent and long hospital stays. 
Sample
 Data were collected by performing a retrospective chart review study in the US and 5EU (France, Germany, Italy, Spain, UK) with physicians recruited from an online panel. Survey was fielded from 04/14 to 05/14 and physicians were asked to report on patients being treated or managed in the past 12 months.
 Physicians (n=211) provided clinical information on 1 to 4 of their RRDTC patients in an online survey. They were recruited through an online panel of physicians and were contacted based on specialty so that experience with RRDTC patients could be maximized. Original sample included 231 physicians; 20 physicians and their respective charts were excluded in the final analysis (primarily if they did not meet the minimum completion time requirement).
 Demographics, disease history, treatment information, and healthcare resource were included and reported descriptively for each patient (n=623).
Measures

Physicians:
 Demographics and Practice Characteristics:
 Demographics: Gender, age, and country were collected for each physician.
 Practice Characteristics: Specialty and primary practice were also collected.
Patients:
 Demographics and Disease History:
 Demographics: Gender and age were reported for each of the patients.
 Disease History: Tumor histology, location or regional recurrence, % metastatic, location of metastases.
Grouping Variable:
 Current RRDTC Management: Participants were categorized into type of RRDTC management based on the physician-reported medication or management type: 
Outcomes:
 Healthcare Resource Use: Frequency of three different forms of healthcare resources over the past 12 months: Office visits with current physician in the past 12 months and hospitalizations in the past 12 months due to disease-associated or treatment-associated side effects. Additionally, hospitalizations over time (collectively) will be reported for disease-associated or treatment-associated side effects.
Statistical Analysis
 Descriptive statistics were conducted for physician demographics and characteristics as well as patient demographics and treatment information.
 General linear models were then conducted to determine the association of management classes with resource use.
Physician Demographics and Characteristics
 Physicians were predominantly male and 35-54 years old. Most worked in a single specialty practice and were medical oncologists.
Patient Demographics and Disease History
 Patients were majority female and 58.2 years old on average.
 Papillary Thyroid Cancer was experienced in more than half the patients as well as about a quarter of the patients experiencing regional recurrence in the bed/central neck area.
 Lastly, slightly over half the patients experienced metastases, with the most common sites of metastases in the bones, lymph nodes, and lungs.
Current Management
 Overall, of those on active systemic treatment, the most common form of management was MKIs. The least common form of management was selective BRAF-inhibitors. Combined for US and 5EU, about 51% of the sample was on systemic treatment with the other 49% either being monitored in a WW period or were receiving local therapy only.
 There were significant differences between the US and 5EU regarding current forms of RRDTC management.
 Cytotoxic chemotherapy and Non-systemic management were more common in 5EU and MKIs were more common in the US. There were no differences for selective BRAFinhibitors.
Physician Visits by Management Type
 Those receiving selective BRAF-inhibitors visited the physician in the previous12 months more than other management options. Those on MKIs went to the physician more frequently than those on non-systemic management who went to the physician the least**.
Hospitalizations in the Past 12 Months
 On average, patients were reported to have 0.56 hospitalizations in the past 12 months due to disease-associated and treatment-associated complications. There were no significant differences between management types.
Hospitalizations Collectively
 On average, patients were reported to have 15.26 hospitalizations collectively for either treatment-associated or disease-associated complications. There were no significant differences between management types.
 An inherent limitation of most retrospective medical record abstractions, respondents selected for study inclusion will represent a convenience sample.
 Because of the reliance on self-reported data pulled by physicians from charts, as well as some subjective measures reported by physicians, recall biases may introduce additional measurement error.
 In particular, hospitalization data should be interpreted with caution as physicians may not have record of hospitalizations and are relying on patient report.
 Additionally, there is difficulty in separating patients into groups based on pace of disease progression and cancer specific symptoms so some with more progressive disease may naturally be in certain management types over others (e.g., MKIs versus non-systemic management).
 Lastly, because of our recruitment and inclusion criteria, it is possible that our sample consists of RRDTC patients with more severe disease thus limiting generalizability to the entire RRDTC population.
 Among patients diagnosed with RRDTC, WW and non-systemic management options remain common.
 Only about half of those diagnosed with RRDTC are currently receiving systemic treatment.
 Of those on systemic treatment, MKIs are the most commonly prescribed treatment. Cytotoxic chemotherapies are also very commonly prescribed.
 Our findings show that patients receiving BRAF-inhibitors and MKIS visited the physician more often in the previous 12 months than those on non-systemic management. However, we do not know the reason for the visits (e.g., scheduled visit for clinical trial, routine check-up, etc.) as the reasons for visits may vary among the groups.
 There were no significant differences in the rate of hospitalizations between those receiving MKIs, cytotoxic chemotherapy, selective BRAF-inhibitors, or non-systemic management. However, overall a large direct-cost burden exists given the frequent hospital stays for these patients. 
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